
    
      This study will evaluate the safety and pharmacokinetics (PK) of delafloxacin in healthy
      adult participants by assessing the intrapulmonary disposition in adults receiving 300 mg
      delafloxacin IV every 12 hours for a total of 7 doses over 4 days.
    
  